ABSTRACT
INTRODUCTION
he term "Portal vein thrombosis" refers to the development of thrombosis within the extrahepatic portal venous system with possible extension downstream to the intrahepatic portal vein branches or upstream to the superior mesenteric and splenic veins (1).
PVT is an important complication of liver cirrhosis. Its reported incidence in compensated disease is between 0.6% and 5%, but becomes much higher (up to 25%) in advanced disease (2). Hepatocellular carcinoma is the most frequent cause of PVT in cirrhosis, being present in up to 44% of cases, and always it has to be searched or when a new diagnosis of PVT is made (3).PVT in patients with HCC is associated with worsened survival (4). Clinical presentation always depends on the onset and the extent of the thrombosis and the development of collateral circulation. In acute PVT Intestinal congestion and ischemia are typical manifestations ; acute abdominal pain , rectal bleeding, fever, splenomegaly and sepsis might be variably present (5). If the obstruction is not resolved quickly, intestinal perforation, peritonitis, shock, and death from multiorgan failure might occur (6) . On the other hand, chronic PVT can be nearly asymptomatic and incidentally detected following aroutine imaging procedure. Patients with chronic PVT present with portal hypertension related complications like oesphageal varices, splenomegaly, anaemia and thrombocytopenia (7) . Although spontaneous resolution of PVT has been reported in the literature (8) , a specific therapeutic management is mandatory to resolve portal vein obstruction and avoid serious complications. The T goal of treatment is similar correction of causal factors, prevention of thrombosis extension, and achievement of portal vein patency (9) . Therefore, the aim of our study was to clarify the risk factors , clinical presentation and complications of portal vein thrombosis in patients with liver cirrhosis and to study the out come after short term follow up.
SUBJECTS AND METHODS This work has been carried out in collaboration between the Internal Medicine , radiology and Clinical pathology Departments, Faculty of Medicine, Zagazig University, during the period from January 2011 to June 2013.
* Subjects:
A total number of 80 patients with cirrhosis were included and were classified into two main groups: 1) Group Written consents were taken from all patients included in the study . Results and possible adverse effects of the anticoagulation therapy were explored to all patients received anticoagulation therapy * Methods: All subjects of the study were subjected to the following:-A) Thorough history and full clinical examination.
B) Routine investigations:
They were all done according to the methods applied in the laboratories of zagazig university hospitals and included: 1-Complete blood picture (by automated blood counter). 2-Liver function tests: serum bilirubin (total and direct), serum albumin, serum ALT and AST by kinetic method 3-Renal function tests: serum creatinine , urea . 4-coagulation profile : PT,PTT and INR. 5-Diagnosis of viral hepatitis by viral markers :-HCV by HCV antibodies and HBV by HBsAg.  Diagnosis of liver cirrhosis :-is done by physical signs, laboratory, and ultrasound findings and severity of the liver disease was scored according to Child's-Pugh score . C-Special Investigations : include 1-Meaurment of protein C and by ELISA:-2-Meaurment of protein S and by ELISA:-Specimen collection and preparation :-Plasma collected with either 3.2% or 3.8% sodium citrate as an anticoagulant should be used as the sample matrix. Blood should be collected by venipuncture, and the sample centrifuged immediately. Remove the plasma and store at 2 -8°C until testing can be performed. If not tested within 8 hours of collection, the sample should be stored at -70°C and tested within 1 month. 3-Diagnosis of portal vein thrombosis :-is done by doppler ultrasound and contrast enhanced triphasic CT in some cases(patients with HCC and in cases with acute onset especially when SMV affection was suspected).  PVT was classified as complete or partial if thrombus determined absence or reduction of blood flow in the main portal trunk, left and right lobar branches, superior mesenteric vein and splenic vein; the presence of a portal cavernoma was evaluated.  PVT was defined asymptomatic if thrombosis was occasionally revealed during a routine ultrasound examination and symptomatic when the patient was admitted because of one or more of pvt complications either acute or chronic. . Quantitative data were expressed as meanstandard deviation (SD) or standard error (SE). SE=SD/square root of patients number which was used in case of big SD, data were analyzed by independent sample, paired t test and one way analysis of variance (ANOVA). While qualitative data were expressed as number and percentage and were analyzed by Chi square (X2) test. Correlation was done using Pearson correlation test. The receiver operating characteristic (ROC) curve and 95% confidence interval (CI) was performed to determine cutoff values for the studied biomarkers. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were determined. P-value was considered significant if <0.05 and highly significant if <0.001. Table ( 1) describes Etiology of liver diseases among both groups , there are no statistical significance differences between both groups as regard etiology of liver diseases as (P>0.05). Table ( 1) describes the local risk factors it shows that HCC ,abdominal intervention (11 cases with splenctomy ,2cases with chemoemboliezation for HCC,2casses with radiofrequency ablation for HCC ,2 cases with cholycystectomy,one case with appendctomy and one case shows drainage for complicated liver abcess ) and abdominal infection (20 cases with sbp and one case with liver abcesses) were statistically significant in pvt group than in control group as (P<0.05).Although prevelance of abdominal inflammation 9 cases(5 cases of cholycystitis and 4 cases of appendicitis) and previous sclerotherapy is higher in pvt group than in control group it is statistically in significant . Table ( 5) shows protein C and S level between both groups.there are no significant difference in both groups as regard Child A. but there were significant reduction of protein C and S level in PVT group than control group as regard Child B and C . Table ( 7) shows changes in platelet count in both groups,there is decease in platelet count with increase severity of liver disease in both groups . In patients with child C there were significant increase in platelet count in PVT group in comparison with control group. But in patients with child A and B ,there were no significant difference between both groups 
RESULTS

Table (1): Etiology of liver diseases
There is no correlation between extension of pvt and clinical presentation except when SMV is involved was never asymptomatic Recurrent upper gi bleeding is highly statistically significant in pvt group than control group as regard follow up There are no statistical significant differences between both groups as regard cause of death.
DISCUSSION
The liver has many haemostatic functions, including the synthesis of most coagulation factors and inhibitors as well as fibrinolytic factors .The balance between procoagulant and anticoagulant factors is essential to to prevent excessive blood loss from injured vessels and to prevent spontaneous thrombosis (10). Thus, the global effect of liver disease with regard to hemostasis is complex, so that patients with advanced liver disease can experience severe bleeding or even thrombotic complications (11). PVT is common in patients affected by liver cirrhosis, with a risk related to the severity of the disease; the prevalence ranges from 1%, at the earlier stages, to 30% in candidates for liver transplantation, (12) . Moreover, in patients with a hepatocellular carcinoma, the incidence of PVT rises to 10%-40%. Figures vary widely depending on how long ago the study was conducted, the diagnostic tool used and the inclusion or exclusion of patients with hepatocellular carcinoma (HCC).
(7).
As already mentioned, PVT in patients with liver disease is the result of concomitant local and systemic thrombophilic factors (13) .Our study demonstrated that malignancy (HCC) was the most common local risk factor for pvt (60%) followed by abdominal infection esp sbp (42%) then abdominal intervention especially splenectomy(40 Portal Vein Thrombosis In Patients With Liver ……… %) .These results also were reported by other studies with different distribution as the study done by Sogaard et al., (6) in which abdominal inflamation esp. pancreatitis is the most common(19 %) followed by cancer (13 %) then abdominal intervention (8 %) .This is due to high prevelance of HCC in our country and high prevelance of pancreatitis abroad. As regard HCC, 22 patients had multiple focal lesions 8 had single lesion , most of them were large . 15 patients were classified as category D and 8 as category C and 5 as category A and B according to BCLC staging for HCC .21 patients were stage C and 5 were stage B and 2 were stage A according to CTP classifications, these results come with agreement with the result reported by Gregory etal.,(4) which demostrated that advanced tumor stage, higher CTP classification,multifocal tumor and were associated with incresed risk of PVT . Previous endoscopic sclerotherapy, even if more frequent in patients with PVT than in those without PVT, did not show statiscal significance which goes in agreement with Mangia et al ., (14 ) and Francoz et al., (15) this is opposite to study was done by Amitrano et al.,(16) which demonstrated that endoscopic sclerotherapy of esophageal varices may represent a trigger factor for portal vein thrombosis in cirrhotic patients. liver cirrhosis is generally associated with profound alterations of the coagulation and anticoagulation systems.For example, INR and PTT, both important parameters indicating coagulation functions, were significantly prolonged in severe liver cirrhosis, which was cleared by our data in the present study. Our study showed that patients with advanced liver cirrhosis and PVT show a significantly lower PTT and INR compared with those without PVT. In patients with early stages of liver cirrhosis, there were no differences in PTT and INR between the PVT and control group. The PLT level was decreased also with advanced stages of liver disease, Zarbock et al.,(17). .In patients with Child A and B ,there were no significant diffierences between the two groups,while in patients with Child C the platelet count was relatively higher in PVT group than controls.Similar reults were in agreement with studies by Francoz et al. (15) and Donglei et al., (9) who reported that cirrhotic patients with PVT had higher platelet level in comparison with cirrhotics without PVT with advanced stages of liver disease. Therefore, patients with advanced liver cirrhosis and not so prolonged coagulation parameters appear to carry a higher risk of PVT compared with patients advanced liver cirrhosis and markedly prolonged coagulation parameters. These findings were also reported by Weber et al., (20) As regard protein C and S ,our study showed that in early stage of liver cirrhosis,there were no differences betweeen both groups.But with increasing severity of liver disease protein Cand S level were significantly decreased in pvt group in comparison with control group,the same results were also reported by Tacke et al.,(21) and Donglei et al., (19) . One of the underlying mechanisms may be due to the fact that hepatocytes fail to synthesize adequate amounts of PC and PS under ischemic and hypoxic conditions. Also, the decrease in PC and PS may be attributed to the endothelial cells damage caused by portal hypertension, which leads to the activation and subsequent consumption of PC and PS in fibrolytic processes . Clinical presentation always depends on the onset and the extent of the thrombosis and the development of collateral circulation(Northup et al .,2008) 15 (30 %) patients were asymptomatic and accedientally discovered during routine ultrasound examination, 15(30%) patients presented with complications of liver cell failure as aggrevation of ascites and hepatic encephalopathy,14(28 %)patients presented with upper git bleeding ,5 (10 %) patients presented with acute abdominal pain and only one patient(2%) presented with lower git bleeding .similar results reported by Amitrano et al., (13) in their study on 79 cirrhotic patients with PVT( 43%)were asymptomatic and (39%) presented with upper git bleeding ,(17%) presented with abdominal pain (7.9 %) presented with intestinal infarction. The presence of complete occlusion of superior mesentericvein was never asymptomatic and presented with the clinical features of intestinal ischemia or infarction. It depends mostly on the absence of an efficient collateral circulation in the mesenteric bed. Conversely a complete thrombosis of main portal trunk or in right or left branche swas symptomless in many patients and we could not find a relationship between the extension of portal thrombosis and the risk of gastrointestinal bleeding .Similar findings were supported by Amitrano etal., (13) . Follow up :-Strict 6 months follow up had occurred for all patients ,revealed that Spontaneous resolution of the thrombosis had occurred in one case without treatment, but the frequency of partial or complete recanalization appeared to be higher in patients treated with anticoagulation therapy . Six patients were selected according to criteria reported by Xingshun et al., (22) and anticoagulation in the form of (low molecular weight heparin and oral warfarin) were adminstered to the patients with INR adjustment (from 2 to 2.5). The critera of patients were as follow ,three patients had main stem thrombosis (1 partial and 2 complete ) and one patient with complete main stem thrombosis and exted to left branch the remainning two patients had complete thrombosis and extended to SMV. The results were , complete recanaliztion had occurred in two cases (33.3%) , partial recanalization had occurred in three patients (50 %) and no change had occurred in one case (16.6 %). similar results also were reported by Senzolo et al.,(23) who made study on 39 cirrhotic pvt patients with anticoagulant admistration showed recanalization of 16 patients (41 %)in comparison with no recanalization in patients not given anticoagulant. Inspite of anticoagulation therapy to cirrhotic patients ,there were no bleeding episodes during the follow up period , which came in agreement with study was made by Buteral et al .,(24) , who gave anticoagulant therapy to sixteen cirrhotic patients with PVT with oesphageal varcices, threre were no evidence of bleeding. Frequent complications during follow-up, in non treated patients , were detected as new onset of varices,recurrent upper git bleeding and aggrevation of liver decompenastion . A larger part of patients with chronic PVT developed oesophageal varices in comparison with patients with acute PVT. These results come with agreement with the result reported by Janssen et al.,(25). Thus, the development of varices is a time dependent phenomenon, and it is advisable to screen all PVT patients endoscopically. The recurrence of upper git bleeding was higher in PVT group (46 %) than in control group (16.6%)and ,these results were similar to results of study done by sogaard et al., (6) in which the recurrence rate was (43%) and higher than recurrence rate in the study done by Zargar et al., (26) in which the recurrence rate in PVT group was (19.4). The results were higher in our study may be due to inclusion of patitents with HCC in our study and not present in study of Zargar et al., (26) .The grade of oesphageal varices and gastropathy were also higher in pvt group than in control group(19.04%) grade II,(28.5%) grade III and (33.3%) grade IV, similar results reported by sogaard et al., (6) in which (11%) were grade II and (26%) were grade III and (33%) grade IV. There were no stastical difference as reguard recurrence of hepatic encephalopathy during the follow up period. As regard mortality , mortality was 20% in PVT patients without HCC incomparison to 5% in other group without HCC which were near to results reported by soggard et al., (6) in which mortality rate were (26 %) and Ferreira et al., (27) in which mortality rate was (24%) and mortality was 83.3 % in PVT patients with HCC incomparison to 30% in other group with HCC which was near to results of a study by Gregory et al.,(4) which demonstrated that the median survival in patients with PVT and HCC was 2.3 months compared to 17.4 months in HCC patients without PVT. Causes of death are recurrent upper GIT bleeding(37.9 %), sepsis (10.3 %),renal failure(20.7%) and DIC (6.9 %). In comparison with other group in which 4 patients only (13.3%)died . On conclusion, Portal vein thrombosis occurs mostly in a cirrhotic patient with advanced liver disease; it is completely asymptomatic in half of cases but when symptomatic, it presents with lifethreatening complications as gastrointestinal bleeding or intestinal infarction. Partial/complete recanalization was more frequent in patients treated with anticoagulation therapy than without treatment .Anticoagulation therapy in cirrhotic patients with pvt were not associated with increased risk of recurrent upper GIT bleeding. 
